Zacks Research raised its Q3 2025 earnings estimate for Pfizer from $0.83 to $0.90 per share. Analysts predict full-year ...

Equities researchers at Zacks Research raised their Q3 2025 earnings estimates for Pfizer in a report issued on Monday, February 24th. Zacks Research analyst K. Shah now forecasts that the ...

The best dividend stocks to buy now are companies that provide significant paydays and stability. After all, a 5% dividend is cold comfort if the share price of your investment drops 50%. That means ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

The London Company Large Cap portfolio returned 0.8% during the quarter vs. a 2.0% decrease in the Russell 1000 Value Index.

The London Company Large Cap portfolio returned 0.8% during the quarter vs. a 2.8% increase in the Russell 1000 Index.

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Thanks to rising electricity demand and infrastructure expansion, the utilities sector is making a strong comeback. Amid this ...

Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ future pipeline to focus more on complex generics—drugs that have ...

DelveInsight's High Potency Active Pharmaceutical Ingredients Market Insights report provides the current and forecast market analysis, individual leading high potency active pharmaceutical ...

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...